Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Drug Reverses Anticoagulant Effects of Common Blood Thinner

July 15, 2015 11:50 am | by Northwestern University | News | Comments

An investigational drug has been shown to reverse the anticoagulant effects of dabigatran in patients who present with bleeding or need for emergent surgery. Dabigatran, sold under the brand name Pradaxa, is a blood-thinner used to prevent strokes in patients with the heart condition atrial fibrillation. Read more...

TOPICS:

20 Health Care Innovators Selected for Aspen Institute Fellowship

July 15, 2015 11:44 am | News | Comments

The Aspen Institute today named 20 health care leaders selected to participate in the inaugural class of its Health Innovators Fellowship. This new two-year Fellowship will strengthen the leadership of innovators across the US health care ecosystem and challenge them to create new approaches that will improve the health and well-being of all Americans. Read more...

TOPICS:

Ebola Vaccine Trial Begins in Senegal

July 15, 2015 9:02 am | by University of Oxford | News | Comments

The announcement comes as a conference in Oxford discusses the global response to Ebola and the implications for future drug and vaccine development. Read more...

TOPICS:
Advertisement

Celgene will Buy Drug Developer Receptos for $7.32B

July 15, 2015 8:53 am | by The Associated Press | News | Comments

Celgene agreed to pay $232 per share for Receptos, and the companies valued the deal at $7.2 billion excluding Receptos' cash on hand. Read more...

TOPICS:

GSK, Francis Crick Institute to Partner on Open R&D Projects

July 15, 2015 8:46 am | News | Comments

This is the first collaboration to be established between the Crick and a pharmaceutical company. Read more...

TOPICS:

More than 200 Poles Sickened by 'Designer Drugs'

July 15, 2015 8:40 am | by The Associated Press | News | Comments

The drugs consist of powerful psychoactive substances sold as powders or ground leaves with warnings that they not be ingested, language that has so far allowed them to be sold in a legal gray zone. Read more...

TOPICS:

Anti-hypertensive Therapeutics Market Value in Asia Pacific to Approach $20B by 2021

July 15, 2015 8:40 am | by Aswini Nath, Analyst, GBI Research | Articles | Comments

Japan is the largest anti-hypertensive therapy market among the four APAC countries, valued at $8.1 billion in 2014 and representing 52 percent of the region’s anti-hypertensive treatment space. Read more...

TOPICS:
Advertisement

J&J Tops Street 2Q Forecasts

July 14, 2015 12:16 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Restrained spending and a sizeable one-time gain helped health giant Johnson & Johnson post a 4.4 percent increase in second-quarter profit, despite lower sales in all three business segments and in every region as unfavorable currency exchange rates shaved revenue. Read more...

TOPICS:

Treating More Adults with Statins Would Be Cost-Effective Way to Boost Heart Health

July 14, 2015 12:12 pm | by Harvard Public Health | News | Comments

A new study from Harvard T.H. Chan School of Public Health researchers has found that it would be cost-effective to treat 48-67% of all adults aged 40-75 in the U.S. with cholesterol-lowering statins. Read more...

TOPICS:

Unilens Signs Definitive Agreement To Be Acquired By Valeant Pharmaceuticals

July 14, 2015 12:06 pm | News | Comments

Unilens Vision Inc. announced today that they have entered into a definitive agreement under which a subsidiary of Valeant Pharmaceuticals International, will acquire all of the outstanding common stock of Unilens Vision Inc. (Unilens) for $12.75 per share in cash, or a total enterprise value of approximately $28 million, which includes approximately $5 million in debt. Read more...

TOPICS:

PhRMA, Epilepsy Foundation Report More Than 400 Neurological Disorder Medicines in Development

July 14, 2015 12:03 pm | News | Comments

America's biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer's disease, multiple sclerosis (MS) and Parkinson's disease. Read more...

TOPICS:

ANI Acquires 22 Generic Drug Products from Teva for $25 million

July 14, 2015 11:55 am | News | Comments

ANI Pharmaceuticals, Inc. ("ANI") today announced that it has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales. Read more...

TOPICS:

Study: Silent Cancer in Moms A Rare Result in Prenatal Tests

July 14, 2015 11:35 am | by By Lindsey Tanner, AP Medical Writer | News | Comments

For pregnant women, abnormal results from certain prenatal tests may signal that something is wrong - with the moms-to-be, not the fetus, a preliminary study suggests. Read more...

TOPICS:

Hepatitis C Medications Found Cost-Effective by Panel

July 14, 2015 11:03 am | by Stephanie Guzowski, Editor | News | Comments

A panel comprised of physicians, health care workers and scientists have recommended that hepatitis C treatments with list prices of $1,000 per daily dose are cost-effective, according to a draft of their report obtained by Bloomberg Business. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading